Seda Eren Keskin
Seda Eren Keskin has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Deniz Sünnetçi Akkoyunlu
Department of Medical Genetics, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
3 shared publications - Naci Cine
Department of Medical Genetics, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
3 shared publications - Buket Doğruoğlu
KOCAELİ ÜNİVERSİTESİ, SAĞLIK BİLİMLERİ ENSTİTÜSÜ, TIBBİ GENETİK VE MOLEKÜLER BİYOLOJİ (DR)
2 shared publications - Zeynep Ilkay
KOCAELİ ÜNİVERSİTESİ, SAĞLIK BİLİMLERİ ENSTİTÜSÜ, TIBBİ GENETİK VE MOLEKÜLER BİYOLOJİ (DR)
2 shared publications - Devrim Çabuk
Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41380, Türkiye
1 shared publication - Eda Guzdolu
KOCAELİ ÜNİVERSİTESİ, SAĞLIK BİLİMLERİ ENSTİTÜSÜ
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Walter de Gruyter GmbH in Open Chemistry
- Vol. 24 (1)
Toxicity assessment of phthalates and binary mixtures on differentiated three-dimensional pancreatic cell model
Currently, the development of new in vitro models and the enhancement of existing ones are increasingly prioritized to significantly reduce laboratory animal use, in line with the 3R principles (replacement, reduction, and refinement) of animal welfare legislation. This study aims to evaluate the cytotoxic effects of individual and binary mixtures of selected phthalates on differentiated pancreatic cell models-islet-like cell aggregates (ICA), developed from human pancreatic carcinoma (PANC-1) cells. In this study, PANC-1 cells are differentiated into ICA which was confirmed by microscopy imaging and the determining the levels of insulin, glucagon, somatostatin and stem cell factor (cKIT) by ELISA assay. Expression levels of NGN3, ISL-1, INS, GCG, PDX and SST marker genes were evaluated by RT-qPCR. Differentiated cells are exposed to diethyl phthalate (DEP), dimethyl phthalate (DMP), dibutyl phthalate (DBP) and diisobutyl phthalate (DiBP). IC50 values were calculated as 870.215, 571.390, 589.219 and 388.471 µM, respectively, for DEP, DMP, DBP and DiBP. All binary mixtures displayed antagonism starting from IC10 values, except, DMP + DBP mixture displayed synergism at the IC90 level.
- 1 January 2026
- Published by Walter de Gruyter GmbH in Open Chemistry
- Vol. 24 (1)
Open AccessToxicity assessment of phthalates and binary mixtures on differentiated three-dimensional pancreatic cell model
Currently, the development of new in vitro models and the enhancement of existing ones are increasingly prioritized to significantly reduce laboratory animal use, in line with the 3R principles (replacement, reduction, and refinement) of animal welfare legislation. This study aims to evaluate the cytotoxic effects of individual and binary mixtures of selected phthalates on differentiated pancreatic cell models-islet-like cell aggregates (ICA), developed from human pancreatic carcinoma (PANC-1) cells. In this study, PANC-1 cells are differentiated into ICA which was confirmed by microscopy imaging and the determining the levels of insulin, glucagon, somatostatin and stem cell factor (cKIT) by ELISA assay. Expression levels of NGN3, ISL-1, INS, GCG, PDX and SST marker genes were evaluated by RT-qPCR. Differentiated cells are exposed to diethyl phthalate (DEP), dimethyl phthalate (DMP), dibutyl phthalate (DBP) and diisobutyl phthalate (DiBP). IC50 values were calculated as 870.215, 571.390, 589.219 and 388.471 µM, respectively, for DEP, DMP, DBP and DiBP. All binary mixtures displayed antagonism starting from IC10 values, except, DMP + DBP mixture displayed synergism at the IC90 level.
- Open Access
- 27 October 2024
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 7 (3) , 359-361
Bariatrik Cerrahi Sonrası Ortaya Çıkan Mide Adenokarsinomu: Obezite ve Mide Kanseri Arasındaki Genetik İlişkinin İncelenmesi
Dünya genelinde ciddi bir sağlık sorunu olan obezitenin en etkin tedavisi olarak cerrahi işlemler uygulanmaktadır. Sleeve gastrektomi en sık uygulanan obezite cerrahisi tekniğidir. Obez bireylerde kanser riskinin arttığına dair görüşler mevcuttur. Ancak obezite cerrahisi sonrası da mide kanseri gelişen bazı olgular bildirilmiştir. Morbid obezite tanısı ile sleeve gastrektomi uygulanan bir hastanın ameliyatından 8 ay sonra dispeptik şikayetleri gelişmeye başlamıştır. Tetkikler neticesinde striktür tanısı konulan hastaya gastrik bypass revizyon cerrahisi uygulanmıştır. Hastanın bu operasyonundan sonra da şikayetlerinin devam etmesi üzerine yapılan detaylı incelemede hastaya mide adenokarsinomu tanısı konulmuştur ve hastaya total gastrektomi ameliyatı yapılmıştır. Obezite ciddi bir sağlık problemi olmasının yanında beraberinde birçok hastalık içinde risk faktörü olarak değerlendirilmektedir. Obez bireylerde kanser riskinin arttığı yönünde literatürde ciddi çalışmalar mevcuttur. Ancak obezite cerrahisi sonrasında kanser riskinin arttığına yönelik bazı çalışmalar mevcut olsa da henüz genel bir kanı oluşmamıştır. Ancak kanser riski artmış olan obez bireylerde cerrahi tedavi öncesinde kanser taraması amacıyla kontrol endoskopi yapılması ciddi şekilde önerilmektedir.
- 27 October 2024
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 7 (3) , 359-361
Open AccessBariatrik Cerrahi Sonrası Ortaya Çıkan Mide Adenokarsinomu: Obezite ve Mide Kanseri Arasındaki Genetik İlişkinin İncelenmesi
Dünya genelinde ciddi bir sağlık sorunu olan obezitenin en etkin tedavisi olarak cerrahi işlemler uygulanmaktadır. Sleeve gastrektomi en sık uygulanan obezite cerrahisi tekniğidir. Obez bireylerde kanser riskinin arttığına dair görüşler mevcuttur. Ancak obezite cerrahisi sonrası da mide kanseri gelişen bazı olgular bildirilmiştir. Morbid obezite tanısı ile sleeve gastrektomi uygulanan bir hastanın ameliyatından 8 ay sonra dispeptik şikayetleri gelişmeye başlamıştır. Tetkikler neticesinde striktür tanısı konulan hastaya gastrik bypass revizyon cerrahisi uygulanmıştır. Hastanın bu operasyonundan sonra da şikayetlerinin devam etmesi üzerine yapılan detaylı incelemede hastaya mide adenokarsinomu tanısı konulmuştur ve hastaya total gastrektomi ameliyatı yapılmıştır. Obezite ciddi bir sağlık problemi olmasının yanında beraberinde birçok hastalık içinde risk faktörü olarak değerlendirilmektedir. Obez bireylerde kanser riskinin arttığı yönünde literatürde ciddi çalışmalar mevcuttur. Ancak obezite cerrahisi sonrasında kanser riskinin arttığına yönelik bazı çalışmalar mevcut olsa da henüz genel bir kanı oluşmamıştır. Ancak kanser riski artmış olan obez bireylerde cerrahi tedavi öncesinde kanser taraması amacıyla kontrol endoskopi yapılması ciddi şekilde önerilmektedir.
- Open Access
- 30 June 2024
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 49 (2) , 248-259
Cytogenetic evaluation of 661 prenatal samples
Purpose: Fetal karyotyping is commonly used to detect chromosomal abnormalities in high-risk pregnancies. Our study is intended to evaluate the results of fetal karyotyping performed in our laboratory for six years and to determine the frequency of chromosomal abnormalities, thus revealing their clinical significance. Materials and Methods: The cytogenetic results of 661 prenatal samples with an indication for invasive prenatal procedures (amniocentesis, cordocentesis) who had a chromosome analysis and FISH testing between February 2013 and March 2019 were analyzed in our study. Results: A total of 72 (10.8%) abnormal fetal karyotypes were observed in the study group. Trisomy 21 was the most common numerical aberration (29%, n = 23), followed by trisomy 18 (16%, n = 13), trisomy 13 (2.6%, n = 2), triploid (2.6%, n = 2), sex chromosome aneuploidies (5.2%, n = 4), and rare mosaic autosomal aneuploidies (2.6%, n = 2). Inversions (16%, n = 13), inherited translocations (7.8%, n = 6), unbalanced/de novo translocations (6.5%, n = 5), deletions (5.2%, n = 4), additional chromosomes (1.3%, n = 1), isochromosomes (1.3%, n = 1), and derivative chromosomes (1.3%, n = 1) were identified as structural abnormalities. Of the 18 cases that underwent FISH testing, trisomy 18 was detected in 1 case and tetrasomy 12p was detected in 1 case. Conclusion: Fetal karyotyping is still an effective and valuable method in the diagnosis of fetal anomalies and provision of effective genetic counseling. In addition, fetal karyotyping should be supported by complementary methods and advanced technologies for accurate and rapid prenatal genetic diagnosis.
- 30 June 2024
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 49 (2) , 248-259
Open AccessCytogenetic evaluation of 661 prenatal samples
Purpose: Fetal karyotyping is commonly used to detect chromosomal abnormalities in high-risk pregnancies. Our study is intended to evaluate the results of fetal karyotyping performed in our laboratory for six years and to determine the frequency of chromosomal abnormalities, thus revealing their clinical significance. Materials and Methods: The cytogenetic results of 661 prenatal samples with an indication for invasive prenatal procedures (amniocentesis, cordocentesis) who had a chromosome analysis and FISH testing between February 2013 and March 2019 were analyzed in our study. Results: A total of 72 (10.8%) abnormal fetal karyotypes were observed in the study group. Trisomy 21 was the most common numerical aberration (29%, n = 23), followed by trisomy 18 (16%, n = 13), trisomy 13 (2.6%, n = 2), triploid (2.6%, n = 2), sex chromosome aneuploidies (5.2%, n = 4), and rare mosaic autosomal aneuploidies (2.6%, n = 2). Inversions (16%, n = 13), inherited translocations (7.8%, n = 6), unbalanced/de novo translocations (6.5%, n = 5), deletions (5.2%, n = 4), additional chromosomes (1.3%, n = 1), isochromosomes (1.3%, n = 1), and derivative chromosomes (1.3%, n = 1) were identified as structural abnormalities. Of the 18 cases that underwent FISH testing, trisomy 18 was detected in 1 case and tetrasomy 12p was detected in 1 case. Conclusion: Fetal karyotyping is still an effective and valuable method in the diagnosis of fetal anomalies and provision of effective genetic counseling. In addition, fetal karyotyping should be supported by complementary methods and advanced technologies for accurate and rapid prenatal genetic diagnosis.
- Open Access
- 3 October 2022
- Published by Kocaeli Universitesi Saglik Bilimleri Dergisi in Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 8 (3) , 172-178
The Mutation Profiles of K-RAS/N-RAS Genes in Metastatic Colorectal Cancer Patients
Objective: RAS genes are members of the RAS/Mitogen activated protein kinase pathway which is induced by Epidermal Growth Factor Receptor (EGFR). Mutations in genes in this pathway trigger cancer development. In colorectal cancer, mutations in RAS genes cause resistance to EGRF- targeted therapy. In the treatment of metastatic colorectal cancer, EGFR’s monoclonal antibodies are widely used as chemotherapeutic agents. Kirsten-RAS mutations are found in 30-50% and N-RAS mutations are found in 2-3% of colorectal cancer. In this study, we aimed to analyze Kirsten-RAS /N-RAS mutations in patients with metastatic colorectal cancer. Methods: One hundred of metastatic colorectal cancer patients resistant to EGFR- targeted therapy were scanned for the Kirsten-RAS mutations status (exon 2,3,4) and N-RAS mutation status (Exon 2,3,4) by Real-Time PCR (Polymerase Chain Reaction) method. Results: As a result of this study, Kirsten-RAS mutation was found 48% and N-RAS mutation was 1.92%. The most common Kirsten-RAS mutations were in codon 12. The distribution of codon 12 mutations were obtained as G12V (25%), G12D (23%), G12C (14.5%). Conclusion: In our study, the frequencies of Kirsten-RAS and N-RAS mutations were compitable with similar reports. Our results have supported that testing RAS genes mutations have a vital role in identifying patients who benefit from Epidermal Growth Factor Receptor- targeted therapy.
- 3 October 2022
- Published by Kocaeli Universitesi Saglik Bilimleri Dergisi in Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 8 (3) , 172-178
Open AccessThe Mutation Profiles of K-RAS/N-RAS Genes in Metastatic Colorectal Cancer Patients
Objective: RAS genes are members of the RAS/Mitogen activated protein kinase pathway which is induced by Epidermal Growth Factor Receptor (EGFR). Mutations in genes in this pathway trigger cancer development. In colorectal cancer, mutations in RAS genes cause resistance to EGRF- targeted therapy. In the treatment of metastatic colorectal cancer, EGFR’s monoclonal antibodies are widely used as chemotherapeutic agents. Kirsten-RAS mutations are found in 30-50% and N-RAS mutations are found in 2-3% of colorectal cancer. In this study, we aimed to analyze Kirsten-RAS /N-RAS mutations in patients with metastatic colorectal cancer. Methods: One hundred of metastatic colorectal cancer patients resistant to EGFR- targeted therapy were scanned for the Kirsten-RAS mutations status (exon 2,3,4) and N-RAS mutation status (Exon 2,3,4) by Real-Time PCR (Polymerase Chain Reaction) method. Results: As a result of this study, Kirsten-RAS mutation was found 48% and N-RAS mutation was 1.92%. The most common Kirsten-RAS mutations were in codon 12. The distribution of codon 12 mutations were obtained as G12V (25%), G12D (23%), G12C (14.5%). Conclusion: In our study, the frequencies of Kirsten-RAS and N-RAS mutations were compitable with similar reports. Our results have supported that testing RAS genes mutations have a vital role in identifying patients who benefit from Epidermal Growth Factor Receptor- targeted therapy.